Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239460 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT00239460 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 196 participants.
The verdict
NCT00239460, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect of inhaled tiotropium bromide on trough FEV1 and to assess the cardiac effects through 12-lead and Holter ECG monitoring in patients with COPD.
Interventions
- DRUG Tiotropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2003-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239460
The ClinicalTrials.gov registry entry for NCT00239460 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tiotropium is the first listed.
NCT00239460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00239460 about?
NCT00239460 is a clinical study titled "Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD". The objective of this study is to evaluate the effect of inhaled tiotropium bromide on trough FEV1 and to assess the cardiac effects through 12-lead and Holter ECG monitoring in patients with COPD.
What is the current status of trial NCT00239460?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00239460?
The interventions under investigation include: Tiotropium (DRUG).
Who is sponsoring clinical trial NCT00239460?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.